HRP20180962T1 - Liječenje bolesti zgrušavanja primjenom rekombinantnog vwf - Google Patents

Liječenje bolesti zgrušavanja primjenom rekombinantnog vwf

Info

Publication number
HRP20180962T1
HRP20180962T1 HRP20180962TT HRP20180962T HRP20180962T1 HR P20180962 T1 HRP20180962 T1 HR P20180962T1 HR P20180962T T HRP20180962T T HR P20180962TT HR P20180962 T HRP20180962 T HR P20180962T HR P20180962 T1 HRP20180962 T1 HR P20180962T1
Authority
HR
Croatia
Prior art keywords
conflict
diseases
treatment
recombinant vwf
vwf
Prior art date
Application number
HRP20180962TT
Other languages
English (en)
Croatian (hr)
Inventor
Friedrich Scheiflinger
Peter Turecek
Bruce EWENSTEIN
Wing Yen Wong
Tobias M. Suiter
Original Assignee
Baxalta GmbH
Baxalta Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Incorporated filed Critical Baxalta GmbH
Publication of HRP20180962T1 publication Critical patent/HRP20180962T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
HRP20180962TT 2011-06-10 2012-06-11 Liječenje bolesti zgrušavanja primjenom rekombinantnog vwf HRP20180962T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161495884P 2011-06-10 2011-06-10
US201161511901P 2011-07-26 2011-07-26
US201161523790P 2011-08-15 2011-08-15
PCT/US2012/041957 WO2012171031A1 (en) 2011-06-10 2012-06-11 Treatment of coagulation disease by administration of recombinant vwf
EP12728919.7A EP2717905B1 (en) 2011-06-10 2012-06-11 Treatment of coagulation disease by administration of recombinant vwf

Publications (1)

Publication Number Publication Date
HRP20180962T1 true HRP20180962T1 (hr) 2018-10-19

Family

ID=46321496

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180962TT HRP20180962T1 (hr) 2011-06-10 2012-06-11 Liječenje bolesti zgrušavanja primjenom rekombinantnog vwf

Country Status (24)

Country Link
US (2) US9272021B2 (cg-RX-API-DMAC7.html)
EP (3) EP3858375B1 (cg-RX-API-DMAC7.html)
JP (3) JP6347468B2 (cg-RX-API-DMAC7.html)
KR (3) KR20190041032A (cg-RX-API-DMAC7.html)
CN (3) CN107412743B (cg-RX-API-DMAC7.html)
AR (1) AR086904A1 (cg-RX-API-DMAC7.html)
AU (5) AU2012267458A1 (cg-RX-API-DMAC7.html)
BR (1) BR112013031795A2 (cg-RX-API-DMAC7.html)
CA (1) CA2838845C (cg-RX-API-DMAC7.html)
DK (3) DK3412305T3 (cg-RX-API-DMAC7.html)
ES (3) ES2860450T3 (cg-RX-API-DMAC7.html)
FI (1) FI3858375T3 (cg-RX-API-DMAC7.html)
HK (1) HK1257436A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20180962T1 (cg-RX-API-DMAC7.html)
HU (1) HUE039317T2 (cg-RX-API-DMAC7.html)
LT (1) LT2717905T (cg-RX-API-DMAC7.html)
MX (2) MX350582B (cg-RX-API-DMAC7.html)
PL (3) PL3412305T3 (cg-RX-API-DMAC7.html)
PT (3) PT2717905T (cg-RX-API-DMAC7.html)
RU (2) RU2628537C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201604684WA (cg-RX-API-DMAC7.html)
SI (1) SI2717905T1 (cg-RX-API-DMAC7.html)
TR (1) TR201808823T4 (cg-RX-API-DMAC7.html)
WO (1) WO2012171031A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086904A1 (es) * 2011-06-10 2014-01-29 Baxter Int Tratamiento de trastornos de la coagulacion por medio de la administracion de factor recombinante de von willebrand (vwf)
CN102776260B (zh) * 2012-07-26 2015-04-29 上海泰龙生物医药科技有限公司 一种高效表达重组人凝血八因子的方法
DK2796145T3 (da) * 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
FR3034669B1 (fr) 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
CA3020346A1 (en) 2016-04-15 2017-10-19 Baxalta Incorporated Method and apparatus for providing a pharmacokinetic drug dosing regimen
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
AU2018298232B2 (en) * 2017-07-07 2025-04-03 Takeda Pharmaceutical Company Limited Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant VWF
US10632176B2 (en) 2017-07-07 2020-04-28 Baxalta Incorporated Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
CN111670202A (zh) 2018-02-06 2020-09-15 埃博灵克斯股份有限公司 以免疫球蛋白单可变结构域治疗ttp初次发作的方法
EA202092223A1 (ru) * 2018-03-21 2021-02-10 Баксалта Инкорпорейтед Разделение vwf и пропептида vwf хроматографическими методами
CN113645993A (zh) * 2019-02-01 2021-11-12 武田药品工业株式会社 使用重组VWF(rVWF)进行预防性治疗的方法
JP2022547556A (ja) * 2019-09-11 2022-11-14 武田薬品工業株式会社 フォン・ヴィレブランド因子と補体c1qの複合体に関連する治療法
CN115335074A (zh) 2020-02-04 2022-11-11 武田药品工业株式会社 通过施用重组vwf来治疗患有重度冯维勒布兰德病的患者的月经过多
JP2023552281A (ja) * 2020-11-24 2023-12-15 バンド セラピューティクス エルエルシー 出血障害の治療のための組成物および方法
WO2024124136A1 (en) * 2022-12-09 2024-06-13 Vega Therapeutics, Inc. Von willebrand disease animal models

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4638028A (en) 1985-04-08 1987-01-20 Goodyear Tire & Rubber Company Rubber polymerases and methods for their production and use
JPS62502589A (ja) 1985-04-11 1987-10-08 ザ・チヤイルドレンズ・メデイカル・センタ−・コ−ポレ−シヨン フオン・ビルブラント因子
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT406373B (de) * 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405403B (de) * 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
US6864403B1 (en) 1998-10-15 2005-03-08 E. I. Du Pont De Nemours And Company Plant protein disulfide isomerases
US20040014657A1 (en) * 2001-11-05 2004-01-22 Jan Ohrstrom Use of blood coagulation factor XIII for treating haemophilia A
WO2005012354A1 (en) * 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1593388A1 (en) * 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
DK1835938T3 (da) * 2004-12-27 2013-11-04 Baxter Int Polymer-von Willebrand-faktor-konjugater
DK2522717T3 (da) 2006-01-04 2014-04-22 Baxter Int Oligopeptid-frie cellekulturmedier
JP2010529155A (ja) * 2007-06-13 2010-08-26 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 出血性疾患の治療及び予防的処置における血管外投与のためのvwf安定化fviii製剤及びfviiiなしのvwf製剤の使用
WO2009062100A1 (en) 2007-11-09 2009-05-14 Baxter International Inc. Modified recombinant factor viii and von willebrand factor and methods of use
JP2009127455A (ja) 2007-11-20 2009-06-11 Bando Kiko Co Ltd 往復動エンジン
AR069989A1 (es) * 2007-12-28 2010-03-03 Baxter Int Formulaciones de vwf recombinantes
ES2298096B1 (es) * 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
DK2865760T3 (en) 2008-06-24 2018-01-15 Csl Behring Gmbh Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
KR101772674B1 (ko) * 2008-10-21 2017-09-01 박스알타 인코퍼레이티드 동결건조된 재조합 vwf 제제
EP2462231A2 (en) * 2009-08-04 2012-06-13 Baxter International Inc Transgenic mouse lacking endogenous fviii and vwf - a model of hemophilia a
SG10201809632XA (en) 2010-07-08 2018-12-28 Baxalta Inc METHOD OF PRODUCING RECOMBINANT HIGH MOLECULAR WEIGHT vWF IN CELL CULTURE
US20120006800A1 (en) 2010-07-09 2012-01-12 Illinois Tool Works Inc. Weld bead feature communication systems and devices
AR086904A1 (es) * 2011-06-10 2014-01-29 Baxter Int Tratamiento de trastornos de la coagulacion por medio de la administracion de factor recombinante de von willebrand (vwf)

Also Published As

Publication number Publication date
US20160184403A1 (en) 2016-06-30
PT2717905T (pt) 2018-07-02
EP3858375A1 (en) 2021-08-04
KR101969515B1 (ko) 2019-04-16
PL3858375T3 (pl) 2024-05-20
PL2717905T3 (pl) 2018-10-31
SG10202002591QA (en) 2020-05-28
AU2016202299A1 (en) 2016-05-05
RU2019103386A (ru) 2020-08-07
AU2022201518B2 (en) 2025-07-03
CN107412743B (zh) 2021-07-02
EP2717905B1 (en) 2018-05-23
US20120316116A1 (en) 2012-12-13
RU2628537C2 (ru) 2017-08-18
AU2017206235B2 (en) 2019-10-17
SI2717905T1 (sl) 2018-09-28
HUE039317T2 (hu) 2018-12-28
KR20190041032A (ko) 2019-04-19
JP2014516088A (ja) 2014-07-07
DK3858375T3 (da) 2024-04-15
ES2976169T3 (es) 2024-07-24
PT3412305T (pt) 2021-01-29
US9272021B2 (en) 2016-03-01
AU2012267458A1 (en) 2014-01-09
CN108210889A (zh) 2018-06-29
LT2717905T (lt) 2018-10-10
KR102319868B1 (ko) 2021-11-01
CA2838845A1 (en) 2012-12-13
KR20140039285A (ko) 2014-04-01
RU2019103386A3 (cg-RX-API-DMAC7.html) 2022-01-24
JP2017019788A (ja) 2017-01-26
AR086904A1 (es) 2014-01-29
JP6527114B2 (ja) 2019-06-05
KR20200091476A (ko) 2020-07-30
JP2019048892A (ja) 2019-03-28
HK1257436A1 (zh) 2019-10-18
FI3858375T3 (fi) 2024-04-17
MX350582B (es) 2017-09-11
DK2717905T3 (en) 2018-07-02
RU2680402C2 (ru) 2019-02-21
ES2860450T3 (es) 2021-10-05
JP6347468B2 (ja) 2018-06-27
DK3412305T3 (da) 2021-03-01
WO2012171031A1 (en) 2012-12-13
RU2017102679A3 (cg-RX-API-DMAC7.html) 2018-12-19
AU2017206235A1 (en) 2017-08-03
MX2013014543A (es) 2014-06-11
AU2022201518A1 (en) 2022-03-24
ES2682249T3 (es) 2018-09-19
AU2020200026A1 (en) 2020-01-30
CN103732244A (zh) 2014-04-16
TR201808823T4 (tr) 2018-07-23
SG10201604684WA (en) 2016-07-28
MX2020000083A (es) 2020-08-06
EP3412305A1 (en) 2018-12-12
CN107412743A (zh) 2017-12-01
BR112013031795A2 (pt) 2016-12-20
EP3858375B1 (en) 2024-03-20
NZ618790A (en) 2015-07-31
EP3412305B1 (en) 2021-01-06
RU2017102679A (ru) 2018-12-19
CA2838845C (en) 2019-08-06
RU2014100107A (ru) 2015-07-20
PT3858375T (pt) 2024-04-18
PL3412305T3 (pl) 2021-05-31
EP2717905A1 (en) 2014-04-16
AU2016202299B2 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
HRP20180962T1 (hr) Liječenje bolesti zgrušavanja primjenom rekombinantnog vwf
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
EP2723384A4 (en) TREATMENT OF PROTEINOPATHIES
HUE048876T2 (hu) Rákos megbetegedések kezelése
PL2739153T3 (pl) Leczenie raka sutka
EP2673286A4 (en) THERAPEUTIC COMPOUNDS
LT2885010T (lt) Tautopatijos gydymo būdai
CO6930321A2 (es) Curación de tejidos
EP2906208A4 (en) THERAPEUTIC TREATMENT
CO7020866A2 (es) Péptidos terapéuticos
DK2701697T3 (da) Oxidative nethindesygdomme
DK2717692T3 (da) Tetrahydrocannabinol-11-syrer til anvendelse til behandling af fibrotiske sygdomme
EP2771007A4 (en) TREATMENT OF RHINITIS
DK2783256T3 (da) Terapeutiske briller
EP2750709A4 (en) TREATMENT OF KACHEXIE
BR112014023176A2 (pt) Métodos de produção de uma proteína recombinante
IL229081A0 (en) Isoxazolines as therapeutic agents
DK2673363T3 (da) Behandling af angiogenesesygdomme
EP2876162A4 (en) MUCOSA CURE PROMOTER
LT2780003T (lt) Antinksčių nepakankamumo gydymas
EP2804946A4 (en) RECOMBINANT CHO GMT PROTEIN EXPRESSION
ME03589B (me) Terapeutski tretman
EP2742159A4 (en) TREATMENT OF SULPHIDIC SUBSTANCES
EP2793897A4 (en) TREATMENT OF SEBORRHOE
UA22708S (uk) Лампа лікувальна